Plasma protein binding (PPB) strongly affects drug distribution and pharmacokinetic
behavior with consequences in overall pharmacological action. Extended plasma protein …

For decades, Praziquantel (PZQ) is the drug of choice against one of the most afflicting
helminthic diseases worldwide, schistosomiasis. With respect to the fear of upcoming PZQ …

Background Bosutinib is a recently approved ABL inhibitor. In spite of the well-documented
effectiveness of BCR-ABL inhibitors in treating chronic myeloid leukemia, development of …

Introduction This research aims to optimize and predict the effectiveness of imatinib
mesylate (imatinib) in tumors expressing platelet-derived growth factors (PDGF-AA, BB) …

Abstract Introduction Philadelphia chromosome (Ph) is a hallmark of chronic myeloid
leukemia (CML), which exists in more than 90% CML and in 3% to 40% acute lymphoblastic …

Despite the efficacy of imatinib mesylate (IM) in treating chronic myeloid leukemia (CML),
there is a high degree of resistance. Alpha-1-acid glycoprotein may reduce drug efficacy …

The combined use of in vitro (19F-NMR) and in silico (molecular docking) procedures
demonstrates the affinity of a number of human calycins (lipid-binding proteins from ileum …

Chronic myeloid leukaemia (CML) is a myeloproliferative disorder arising in a
haematopoietic stem cell (HSC) and defined by the presence of BCR-ABL1, a deregulated …

In chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
patients resistant to tyrosine kinase inhibitors (TKIs), BCR-ABL kinase domain mutation …

Given the success of first-line treatment in chronic myeloid leukemia (CML), the prevalence
of the disease is estimated to increase and more patients are expected to develop …